227 related articles for article (PubMed ID: 25295955)
1. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
Thiery-Vuillemin A; Mouillet G; Pouessel D; Barthelemy P; Caty A; Sebbagh S; Vanno YA; Laplaige P; Cheverau C; Ravaud A
Bull Cancer; 2014 Sep; 101(9):832-40. PubMed ID: 25295955
[TBL] [Abstract][Full Text] [Related]
2. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
[TBL] [Abstract][Full Text] [Related]
3. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
Bracarda S; Negrier S; Casper J; Porta C; Schmidinger M; Larkin J; Gross Goupil M; Escudier B
Expert Rev Anticancer Ther; 2017 Mar; 17(3):227-233. PubMed ID: 28044472
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
5. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
Buti S; Donini M; Bersanelli M; Gattara A; Leonardi F; Passalacqua R
Drugs R D; 2017 Dec; 17(4):585-596. PubMed ID: 28895069
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
Iwamoto K; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
Med Oncol; 2018 Apr; 35(6):78. PubMed ID: 29687160
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Ezz El Din M
Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
[TBL] [Abstract][Full Text] [Related]
8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
9. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
Miyake H; Harada K; Miyazaki A; Fujisawa M
Med Oncol; 2015 Mar; 32(3):78. PubMed ID: 25698532
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
[TBL] [Abstract][Full Text] [Related]
11. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Ohzeki T; Fukasawa S; Komaru A; Namekawa T; Sato Y; Takagi K; Kobayashi M; Uemura H; Ichikawa T; Ueda T
Int J Urol; 2014 Oct; 21(10):1065-8. PubMed ID: 24930736
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.
Vázquez S; León L; Fernández O; Lázaro M; Grande E; Aparicio L
Adv Ther; 2012 Mar; 29(3):202-17. PubMed ID: 22328304
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
15. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
[TBL] [Abstract][Full Text] [Related]
16. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
18. [A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].
Cui C; Li S; Chi Z; Si L; Sheng X; Mao L; Lian B; Wang X; Tang B; Guo J
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):375-8. PubMed ID: 26463030
[TBL] [Abstract][Full Text] [Related]
19. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.
Neri B; Vannini A; Brugia M; Muto A; Rangan S; Rediti M; Tassi R; Cerullo C
Int J Urol; 2013 May; 20(5):478-83. PubMed ID: 23113655
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
Neri B; Vannini A; Tassi R; Brugia M; Rangan S; Rediti M; Cerullo C
Oncol Res; 2012; 20(5-6):259-64. PubMed ID: 23581233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
